ID   PK2L1_HUMAN             Reviewed;         805 AA.
AC   Q9P0L9; O75972; Q5W039; Q9UP35; Q9UPA2;
DT   10-OCT-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   28-JUN-2023, entry version 181.
DE   RecName: Full=Polycystin-2-like protein 1;
DE            Short=Polycystin-2L1;
DE   AltName: Full=Polycystic kidney disease 2-like 1 protein;
DE   AltName: Full=Polycystin-2 homolog;
DE   AltName: Full=Polycystin-L {ECO:0000303|PubMed:10517637, ECO:0000303|PubMed:9748274};
DE   AltName: Full=Polycystin-L1;
GN   Name=PKD2L1;
GN   Synonyms=PKD2L, PKDL {ECO:0000303|PubMed:9748274}, TRPP3
GN   {ECO:0000303|PubMed:23212381, ECO:0000303|PubMed:27754867};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT
RP   ILE-393.
RC   TISSUE=Retina;
RX   PubMed=9748274; DOI=10.1074/jbc.273.40.25967;
RA   Nomura H., Turco A.E., Pei Y., Kalaydjieva L., Schiavello T.,
RA   Weremowicz S., Ji W., Morton C.C., Meisler M., Reeders S.T., Zhou J.;
RT   "Identification of PKDL, a novel polycystic kidney disease 2-like gene
RT   whose murine homologue is deleted in mice with kidney and retinal
RT   defects.";
RL   J. Biol. Chem. 273:25967-25973(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2; 3 AND 4).
RX   PubMed=10602992; DOI=10.1007/s003350010009;
RA   Guo L., Chen M., Basora N., Zhou J.;
RT   "The human polycystic kidney disease 2-like (PKDL) gene: exon/intron
RT   structure and evidence for a novel splicing mechanism.";
RL   Mamm. Genome 11:46-50(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 96-805 (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Retina;
RX   PubMed=9878261; DOI=10.1006/geno.1998.5618;
RA   Wu G., Hayashi T., Park J.-H., Dixit M., Reynolds D.M., Li L., Maeda Y.,
RA   Cai Y., Coca-Prados M., Somlo S.;
RT   "Identification of PKD2L, a human PKD2-related gene: tissue-specific
RT   expression and mapping to chromosome 10q25.";
RL   Genomics 54:564-568(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 43-805 (ISOFORMS 1 AND 4).
RC   TISSUE=Testis;
RX   PubMed=10602361; DOI=10.1038/sj.ejhg.5200383;
RA   Veldhuisen B., Spruit L., Dauwerse H.G., Breuning M.H., Peters D.J.M.;
RT   "Genes homologous to the autosomal dominant polycystic kidney disease genes
RT   (PKD1 and PKD2).";
RL   Eur. J. Hum. Genet. 7:860-872(1999).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10517637; DOI=10.1038/43907;
RA   Chen X.-Z., Vassilev P.M., Basora N., Peng J.-B., Nomura H., Segal Y.,
RA   Brown E.M., Reeders S.T., Hediger M.A., Zhou J.;
RT   "Polycystin-L is a calcium-regulated cation channel permeable to calcium
RT   ions.";
RL   Nature 401:383-386(1999).
RN   [9]
RP   ALTERNATIVE SPLICING (ISOFORMS 2 AND 5), FUNCTION, SUBCELLULAR LOCATION,
RP   AND DOMAIN.
RX   PubMed=11959145; DOI=10.1016/s0014-5793(02)02513-9;
RA   Li Q., Liu Y., Zhao W., Chen X.Z.;
RT   "The calcium-binding EF-hand in polycystin-L is not a domain for channel
RT   activation and ensuing inactivation.";
RL   FEBS Lett. 516:270-278(2002).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=19812697; DOI=10.1371/journal.pone.0007347;
RA   Huque T., Cowart B.J., Dankulich-Nagrudny L., Pribitkin E.A., Bayley D.L.,
RA   Spielman A.I., Feldman R.S., Mackler S.A., Brand J.G.;
RT   "Sour ageusia in two individuals implicates ion channels of the ASIC and
RT   PKD families in human sour taste perception at the anterior tongue.";
RL   PLoS ONE 4:E7347-E7347(2009).
RN   [11]
RP   DOMAIN, AND CALCIUM-BINDING.
RX   PubMed=20408813; DOI=10.1042/bj20091843;
RA   Molland K.L., Narayanan A., Burgner J.W., Yernool D.A.;
RT   "Identification of the structural motif responsible for trimeric assembly
RT   of the C-terminal regulatory domains of polycystin channels PKD2L1 and
RT   PKD2.";
RL   Biochem. J. 429:171-183(2010).
RN   [12]
RP   INTERACTION WITH RACK1.
RX   PubMed=22174419; DOI=10.1074/jbc.m111.305854;
RA   Yang J., Wang Q., Zheng W., Tuli J., Li Q., Wu Y., Hussein S., Dai X.Q.,
RA   Shafiei S., Li X.G., Shen P.Y., Tu J.C., Chen X.Z.;
RT   "Receptor for activated C kinase 1 (RACK1) inhibits function of transient
RT   receptor potential (TRP)-type channel Pkd2L1 through physical
RT   interaction.";
RL   J. Biol. Chem. 287:6551-6561(2012).
RN   [13]
RP   FUNCTION, SUBUNIT, INTERACTION WITH PKD1L1, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF 523-GLU--GLU-525.
RX   PubMed=24336289; DOI=10.1038/nature12832;
RA   DeCaen P.G., Delling M., Vien T.N., Clapham D.E.;
RT   "Direct recording and molecular identification of the calcium channel of
RT   primary cilia.";
RL   Nature 504:315-318(2013).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, INTERACTION WITH PKD1L3, AND
RP   MUTAGENESIS OF 2-ASN--TYR-96; 566-GLU--SER-805; 581-SER--SER-805 AND
RP   622-THR--SER-805.
RX   PubMed=25820328; DOI=10.1038/srep09460;
RA   Zheng W., Hussein S., Yang J., Huang J., Zhang F., Hernandez-Anzaldo S.,
RA   Fernandez-Patron C., Cao Y., Zeng H., Tang J., Chen X.Z.;
RT   "A novel PKD2L1 C-terminal domain critical for trimerization and channel
RT   function.";
RL   Sci. Rep. 5:9460-9460(2015).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-38, AND MUTAGENESIS
RP   OF 2-ASN--ARG-36; 2-ASN--CYS-38; CYS-38; THR-39; 594-ARG--LYS-599; ARG-594;
RP   ARG-596; ARG-598 AND LYS-599.
RX   PubMed=27754867; DOI=10.1074/jbc.m116.756544;
RA   Zheng W., Yang J., Beauchamp E., Cai R., Hussein S., Hofmann L., Li Q.,
RA   Flockerzi V., Berthiaume L.G., Tang J., Chen X.Z.;
RT   "Regulation of TRPP3 Channel Function by N-terminal Domain Palmitoylation
RT   and Phosphorylation.";
RL   J. Biol. Chem. 291:25678-25691(2016).
RN   [16]
RP   FUNCTION, DOMAIN, ACTIVITY REGULATION, AND MUTAGENESIS OF 81-TRP--LEU-95;
RP   TRP-81 AND LYS-568.
RX   PubMed=29425510; DOI=10.1016/j.celrep.2018.01.042;
RA   Zheng W., Cai R., Hofmann L., Nesin V., Hu Q., Long W., Fatehi M., Liu X.,
RA   Hussein S., Kong T., Li J., Light P.E., Tang J., Flockerzi V., Tsiokas L.,
RA   Chen X.Z.;
RT   "Direct Binding between Pre-S1 and TRP-like Domains in TRPP Channels
RT   Mediates Gating and Functional Regulation by PIP2.";
RL   Cell Rep. 22:1560-1573(2018).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.69 ANGSTROMS) OF 699-737, SUBUNIT,
RP   CALCIUM-BINDING, AND MUTAGENESIS OF LEU-710; VAL-714; LEU-717; ILE-728;
RP   VAL-731 AND LEU-735.
RX   PubMed=22193359; DOI=10.1016/j.bbapap.2011.12.002;
RA   Molland K.L., Paul L.N., Yernool D.A.;
RT   "Crystal structure and characterization of coiled-coil domain of the
RT   transient receptor potential channel PKD2L1.";
RL   Biochim. Biophys. Acta 1824:413-421(2012).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 699-743, FUNCTION, ACTIVITY
RP   REGULATION, SUBUNIT, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-523 AND
RP   ASP-525.
RX   PubMed=23212381; DOI=10.1038/ncomms2257;
RA   Yu Y., Ulbrich M.H., Li M.H., Dobbins S., Zhang W.K., Tong L.,
RA   Isacoff E.Y., Yang J.;
RT   "Molecular mechanism of the assembly of an acid-sensing receptor ion
RT   channel complex.";
RL   Nat. Commun. 3:1252-1252(2012).
RN   [19] {ECO:0007744|PDB:6DU8}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.11 ANGSTROMS), FUNCTION, SUBUNIT,
RP   TOPOLOGY, GLYCOSYLATION AT ASN-207, AND DISULFIDE BOND.
RX   PubMed=30004384; DOI=10.7554/elife.36931;
RA   Hulse R.E., Li Z., Huang R.K., Zhang J., Clapham D.E.;
RT   "Cryo-EM structure of the polycystin 2-l1 ion channel.";
RL   Elife 7:0-0(2018).
CC   -!- FUNCTION: Pore-forming subunit of a heterotetrameric, non-selective
CC       cation channel that is permeable to Ca(2+) (PubMed:10517637,
CC       PubMed:11959145, PubMed:25820328, PubMed:27754867, PubMed:29425510,
CC       PubMed:23212381, PubMed:30004384). Pore-forming subunit of a calcium-
CC       permeant ion channel formed by PKD1L2 and PKD1L1 in primary cilia,
CC       where it controls cilium calcium concentration, but does not affect
CC       cytoplasmic calcium concentration (PubMed:24336289). The channel formed
CC       by PKD1L2 and PKD1L1 in primary cilia regulates sonic hedgehog/SHH
CC       signaling and GLI2 transcription (PubMed:24336289). Pore-forming
CC       subunit of a channel formed by PKD1L2 and PKD1L3 that contributes to
CC       sour taste perception in gustatory cells (PubMed:19812697). The
CC       heteromeric channel formed by PKD1L2 and PKD1L3 is activated by low pH,
CC       but opens only when the extracellular pH rises again (PubMed:23212381).
CC       May play a role in the perception of carbonation taste (By similarity).
CC       May play a role in the sensory perception of water, via a mechanism
CC       that activates the channel in response to dilution of salivary
CC       bicarbonate and changes in salivary pH (By similarity).
CC       {ECO:0000250|UniProtKB:A2A259, ECO:0000269|PubMed:10517637,
CC       ECO:0000269|PubMed:11959145, ECO:0000269|PubMed:19812697,
CC       ECO:0000269|PubMed:23212381, ECO:0000269|PubMed:24336289,
CC       ECO:0000269|PubMed:25820328, ECO:0000269|PubMed:27754867,
CC       ECO:0000269|PubMed:29425510, ECO:0000269|PubMed:30004384}.
CC   -!- ACTIVITY REGULATION: The cation channel is gated following an off-
CC       response property by acid: gated open after the removal of acid
CC       stimulus, but not during acid application (PubMed:23212381). Channel
CC       activity is inhibited by phosphatidylinositol-4,5-bisphosphate (PIP2)
CC       (PubMed:29425510). {ECO:0000269|PubMed:23212381,
CC       ECO:0000269|PubMed:29425510}.
CC   -!- SUBUNIT: Homotetramer (PubMed:25820328, PubMed:30004384).
CC       Heterotetramer with either PKD1L1, PKD1L3 or PKD1; the heterotetrameric
CC       complex probably contains three PKD1L2 chains plus one chain from
CC       another family member (PubMed:25820328, PubMed:23212381). Interacts
CC       with PKD1L1, forming a ciliary calcium channel (PubMed:24336289).
CC       Interacts with PKD1L3, forming a cation channel that is activated by
CC       low extracellular pH (PubMed:25820328, PubMed:23212381). Interacts with
CC       PKD1 (By similarity). Interacts with RACK1; inhibits the channel
CC       activity possibly by impairing localization to the cell membrane
CC       (PubMed:22174419). {ECO:0000250|UniProtKB:A2A259,
CC       ECO:0000269|PubMed:22174419, ECO:0000269|PubMed:22193359,
CC       ECO:0000269|PubMed:23212381, ECO:0000269|PubMed:24336289,
CC       ECO:0000269|PubMed:25820328, ECO:0000269|PubMed:30004384}.
CC   -!- INTERACTION:
CC       Q9P0L9; Q8N6F1-2: CLDN19; NbExp=3; IntAct=EBI-7956847, EBI-12256978;
CC   -!- SUBCELLULAR LOCATION: Cell projection, cilium membrane
CC       {ECO:0000269|PubMed:24336289}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:30004384}. Cell membrane
CC       {ECO:0000269|PubMed:10517637, ECO:0000269|PubMed:11959145,
CC       ECO:0000269|PubMed:23212381, ECO:0000269|PubMed:25820328,
CC       ECO:0000269|PubMed:27754867, ECO:0000269|PubMed:29425510}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:30004384}. Cytoplasmic vesicle
CC       {ECO:0000250|UniProtKB:A2A259}. Note=Interaction with PKD1 or PKD1L3 is
CC       required for localization to the cell membrane.
CC       {ECO:0000250|UniProtKB:A2A259}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q9P0L9-1; Sequence=Displayed;
CC       Name=2; Synonyms=PKDLdel15, PCL-TS, Testis isoform;
CC         IsoId=Q9P0L9-2; Sequence=VSP_004730, VSP_004731;
CC       Name=3; Synonyms=PKDLdel5;
CC         IsoId=Q9P0L9-3; Sequence=VSP_004729;
CC       Name=4; Synonyms=PKDLdel456;
CC         IsoId=Q9P0L9-4; Sequence=VSP_004728;
CC       Name=5; Synonyms=PCL-LV, Liver isoform;
CC         IsoId=Q9P0L9-5; Sequence=VSP_053718;
CC   -!- TISSUE SPECIFICITY: Detected in taste bud cells in fungiform papillae
CC       (at protein level) (PubMed:19812697). Ubiquitous (PubMed:9748274).
CC       Expressed in adult heart, skeletal muscle, brain, spleen, testis,
CC       retina and liver (PubMed:9748274, PubMed:9878261). Isoform 4 appears to
CC       be expressed only in transformed lymphoblasts.
CC       {ECO:0000269|PubMed:19812697, ECO:0000269|PubMed:9748274,
CC       ECO:0000269|PubMed:9878261}.
CC   -!- DOMAIN: The EF-hand domain probably mediates calcium-binding. It is not
CC       required for channel activation (PubMed:11959145).
CC       {ECO:0000269|PubMed:11959145, ECO:0000269|PubMed:20408813}.
CC   -!- DOMAIN: Interaction of the cytoplasmic N- and C-terminal domains is
CC       important for channel activity. {ECO:0000269|PubMed:29425510}.
CC   -!- PTM: Palmitoylation is important for expression at the cell membrane
CC       and for channel activity. {ECO:0000269|PubMed:27754867}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Unusual intron exon spliced junction.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the polycystin family. {ECO:0000305}.
CC   -!- CAUTION: The active channel complex is an obligate tetramer
CC       (PubMed:25820328, PubMed:30004384). In contrast, the isolated
CC       cytoplasmic C-terminal domain forms homotrimers in vitro
CC       (PubMed:20408813, PubMed:25820328, PubMed:23212381). Likewise,
CC       photobleaching experiments suggest formation of homotrimers in the
CC       membrane (PubMed:23212381). {ECO:0000269|PubMed:20408813,
CC       ECO:0000269|PubMed:23212381, ECO:0000269|PubMed:25820328,
CC       ECO:0000269|PubMed:30004384}.
CC   -!- CAUTION: PKD1L3 and PKD2L1 have been defined as sour taste receptor in
CC       gustatory cells based on a number of indirect evidences in mouse. Some
CC       data confirm this hypothesis in human: in 2 patients with sour ageusia
CC       that are unresponsive to sour stimuli, but show normal responses to
CC       bitter, sweet, and salty stimuli, expression of PKD1L3 and PKD2L1 is
CC       absent in the anterior part of the tongue (PubMed:19812697). However, a
CC       number of experiments have recently shown that the sour taste receptor
CC       activity is probably indirect. {ECO:0000305|PubMed:19812697}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF073481; AAD41638.1; -; mRNA.
DR   EMBL; AF153474; AAF28108.1; -; Genomic_DNA.
DR   EMBL; AF153459; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153460; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153461; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153462; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153463; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153464; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153465; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153466; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153467; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153468; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153469; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153470; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153471; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153472; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AF153473; AAF28108.1; JOINED; Genomic_DNA.
DR   EMBL; AL139819; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49833.1; -; Genomic_DNA.
DR   EMBL; BC025665; AAH25665.1; -; mRNA.
DR   EMBL; AF094827; AAD08695.1; -; mRNA.
DR   EMBL; AF053316; AAD51859.1; -; mRNA.
DR   CCDS; CCDS7492.1; -. [Q9P0L9-1]
DR   RefSeq; NP_001240766.1; NM_001253837.1.
DR   RefSeq; NP_057196.2; NM_016112.2. [Q9P0L9-1]
DR   PDB; 3TE3; X-ray; 2.69 A; A/B/C/D/E/F=699-737.
DR   PDB; 4GIF; X-ray; 2.80 A; A=699-743.
DR   PDB; 6DU8; EM; 3.11 A; A/B/C/D=1-805.
DR   PDBsum; 3TE3; -.
DR   PDBsum; 4GIF; -.
DR   PDBsum; 6DU8; -.
DR   AlphaFoldDB; Q9P0L9; -.
DR   SMR; Q9P0L9; -.
DR   BioGRID; 114499; 3.
DR   IntAct; Q9P0L9; 2.
DR   MINT; Q9P0L9; -.
DR   STRING; 9606.ENSP00000325296; -.
DR   DrugBank; DB11093; Calcium citrate.
DR   DrugBank; DB11348; Calcium Phosphate.
DR   DrugBank; DB14481; Calcium phosphate dihydrate.
DR   GuidetoPHARMACOLOGY; 505; -.
DR   TCDB; 1.A.5.1.3; the polycystin cation channel (pcc) family.
DR   GlyCosmos; Q9P0L9; 4 sites, No reported glycans.
DR   GlyGen; Q9P0L9; 4 sites.
DR   iPTMnet; Q9P0L9; -.
DR   PhosphoSitePlus; Q9P0L9; -.
DR   SwissPalm; Q9P0L9; -.
DR   BioMuta; PKD2L1; -.
DR   DMDM; 23821938; -.
DR   MassIVE; Q9P0L9; -.
DR   PaxDb; Q9P0L9; -.
DR   PeptideAtlas; Q9P0L9; -.
DR   ProteomicsDB; 83574; -. [Q9P0L9-1]
DR   ProteomicsDB; 83576; -. [Q9P0L9-3]
DR   ProteomicsDB; 83577; -. [Q9P0L9-4]
DR   Antibodypedia; 31169; 158 antibodies from 22 providers.
DR   DNASU; 9033; -.
DR   Ensembl; ENST00000318222.4; ENSP00000325296.3; ENSG00000107593.17. [Q9P0L9-1]
DR   GeneID; 9033; -.
DR   KEGG; hsa:9033; -.
DR   MANE-Select; ENST00000318222.4; ENSP00000325296.3; NM_016112.3; NP_057196.2.
DR   UCSC; uc001kqx.2; human. [Q9P0L9-1]
DR   AGR; HGNC:9011; -.
DR   CTD; 9033; -.
DR   DisGeNET; 9033; -.
DR   GeneCards; PKD2L1; -.
DR   HGNC; HGNC:9011; PKD2L1.
DR   HPA; ENSG00000107593; Tissue enhanced (brain, lymphoid tissue, retina).
DR   MIM; 604532; gene.
DR   neXtProt; NX_Q9P0L9; -.
DR   OpenTargets; ENSG00000107593; -.
DR   PharmGKB; PA33344; -.
DR   VEuPathDB; HostDB:ENSG00000107593; -.
DR   eggNOG; KOG3599; Eukaryota.
DR   GeneTree; ENSGT00940000157274; -.
DR   HOGENOM; CLU_012097_0_0_1; -.
DR   InParanoid; Q9P0L9; -.
DR   OMA; AFSQFDR; -.
DR   OrthoDB; 56358at2759; -.
DR   PhylomeDB; Q9P0L9; -.
DR   TreeFam; TF316484; -.
DR   PathwayCommons; Q9P0L9; -.
DR   SignaLink; Q9P0L9; -.
DR   BioGRID-ORCS; 9033; 15 hits in 1151 CRISPR screens.
DR   ChiTaRS; PKD2L1; human.
DR   GeneWiki; PKD2L1; -.
DR   GenomeRNAi; 9033; -.
DR   Pharos; Q9P0L9; Tchem.
DR   PRO; PR:Q9P0L9; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q9P0L9; protein.
DR   Bgee; ENSG00000107593; Expressed in spleen and 127 other tissues.
DR   ExpressionAtlas; Q9P0L9; baseline and differential.
DR   Genevisible; Q9P0L9; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0034704; C:calcium channel complex; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0060170; C:ciliary membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0097730; C:non-motile cilium; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; ISS:BHF-UCL.
DR   GO; GO:0051393; F:alpha-actinin binding; IPI:BHF-UCL.
DR   GO; GO:0005227; F:calcium activated cation channel activity; IDA:BHF-UCL.
DR   GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0015269; F:calcium-activated potassium channel activity; IDA:BHF-UCL.
DR   GO; GO:0008092; F:cytoskeletal protein binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISS:BHF-UCL.
DR   GO; GO:0005261; F:monoatomic cation channel activity; IDA:UniProtKB.
DR   GO; GO:0051371; F:muscle alpha-actinin binding; IPI:BHF-UCL.
DR   GO; GO:0005272; F:sodium channel activity; IDA:BHF-UCL.
DR   GO; GO:0033040; F:sour taste receptor activity; IEA:Ensembl.
DR   GO; GO:0071468; P:cellular response to acidic pH; ISS:BHF-UCL.
DR   GO; GO:0001581; P:detection of chemical stimulus involved in sensory perception of sour taste; ISS:BHF-UCL.
DR   GO; GO:0050912; P:detection of chemical stimulus involved in sensory perception of taste; ISS:UniProtKB.
DR   GO; GO:0050982; P:detection of mechanical stimulus; IBA:GO_Central.
DR   GO; GO:0098662; P:inorganic cation transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006812; P:monoatomic cation transport; ISS:BHF-UCL.
DR   GO; GO:0071805; P:potassium ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB.
DR   GO; GO:0009415; P:response to water; IEA:Ensembl.
DR   GO; GO:0050915; P:sensory perception of sour taste; IMP:UniProtKB.
DR   GO; GO:0007224; P:smoothened signaling pathway; ISS:UniProtKB.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IDA:BHF-UCL.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.20.5.340; -; 1.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 1.20.120.350; Voltage-gated potassium channels. Chain C; 1.
DR   InterPro; IPR013122; PKD1_2_channel.
DR   InterPro; IPR003915; PKD_2.
DR   InterPro; IPR046791; Polycystin_dom.
DR   InterPro; IPR027359; Volt_channel_dom_sf.
DR   PANTHER; PTHR10877:SF183; POLYCYSTIC KIDNEY DISEASE 2-LIKE 1 PROTEIN; 1.
DR   PANTHER; PTHR10877; POLYCYSTIN FAMILY MEMBER; 1.
DR   Pfam; PF18109; Fer4_24; 1.
DR   Pfam; PF08016; PKD_channel; 1.
DR   Pfam; PF20519; Polycystin_dom; 1.
DR   PRINTS; PR01433; POLYCYSTIN2.
DR   SUPFAM; SSF81324; Voltage-gated potassium channels; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Calcium channel;
KW   Calcium transport; Cell membrane; Cell projection; Cilium; Coiled coil;
KW   Cytoplasmic vesicle; Disulfide bond; Glycoprotein; Ion channel;
KW   Ion transport; Lipoprotein; Membrane; Metal-binding; Palmitate;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..805
FT                   /note="Polycystin-2-like protein 1"
FT                   /id="PRO_0000164360"
FT   TOPO_DOM        1..103
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TRANSMEM        104..124
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TOPO_DOM        125..356
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TRANSMEM        357..376
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TOPO_DOM        377..384
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TRANSMEM        385..405
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TOPO_DOM        406..433
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TRANSMEM        434..454
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TOPO_DOM        455..479
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TRANSMEM        480..499
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TOPO_DOM        500..511
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   INTRAMEM        512..526
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TOPO_DOM        527..536
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TRANSMEM        537..557
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   TOPO_DOM        558..805
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:30004384"
FT   DOMAIN          633..668
FT                   /note="EF-hand"
FT                   /evidence="ECO:0000255"
FT   REGION          1..59
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          704..763
FT                   /note="Required for homooligomerization"
FT   REGION          759..805
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          650..686
FT                   /evidence="ECO:0000255"
FT   COILED          700..740
FT                   /evidence="ECO:0000269|PubMed:22193359,
FT                   ECO:0000269|PubMed:23212381"
FT   COMPBIAS        779..799
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         646
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
FT   BINDING         648
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
FT   BINDING         650
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
FT   BINDING         657
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
FT   LIPID           38
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:27754867"
FT   CARBOHYD        177
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        207
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:30004384,
FT                   ECO:0007744|PDB:6DU8"
FT   CARBOHYD        241
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        505
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        210..223
FT                   /evidence="ECO:0000305|PubMed:30004384,
FT                   ECO:0007744|PDB:6DU8"
FT   VAR_SEQ         225..344
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10602361"
FT                   /id="VSP_004728"
FT   VAR_SEQ         245..319
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004729"
FT   VAR_SEQ         638..666
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053718"
FT   VAR_SEQ         751..760
FT                   /note="KEQAIWKHPQ -> RFPIKEKRKP (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004730"
FT   VAR_SEQ         761..805
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004731"
FT   VARIANT         278
FT                   /note="R -> Q (in dbSNP:rs17112895)"
FT                   /id="VAR_050555"
FT   VARIANT         378
FT                   /note="R -> W (in dbSNP:rs7909153)"
FT                   /id="VAR_050556"
FT   VARIANT         393
FT                   /note="V -> I (in dbSNP:rs2278842)"
FT                   /evidence="ECO:0000269|PubMed:9748274"
FT                   /id="VAR_024569"
FT   VARIANT         681
FT                   /note="R -> L (in dbSNP:rs6584356)"
FT                   /id="VAR_024570"
FT   VARIANT         788
FT                   /note="A -> D (in dbSNP:rs12782963)"
FT                   /id="VAR_050557"
FT   MUTAGEN         2..96
FT                   /note="Missing: Loss of channel activity. No effect on
FT                   expression at the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:25820328"
FT   MUTAGEN         2..38
FT                   /note="Missing: Loss of channel activity."
FT                   /evidence="ECO:0000269|PubMed:27754867"
FT   MUTAGEN         2..36
FT                   /note="Missing: No effect on channel activity."
FT                   /evidence="ECO:0000269|PubMed:27754867"
FT   MUTAGEN         38
FT                   /note="C->A: Strongly decreased channel activity. No effect
FT                   on expression at the cell membrane. Loss of
FT                   palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27754867"
FT   MUTAGEN         39
FT                   /note="T->D,E: Decreased channel activity."
FT                   /evidence="ECO:0000269|PubMed:27754867"
FT   MUTAGEN         81..95
FT                   /note="Missing: Loss of channel activity."
FT                   /evidence="ECO:0000269|PubMed:29425510"
FT   MUTAGEN         81
FT                   /note="W->A,K,L,R: Loss of channel activity. No effect on
FT                   expression at the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:29425510"
FT   MUTAGEN         523..525
FT                   /note="DFD->AFA: Abolishes ion channel activity."
FT                   /evidence="ECO:0000269|PubMed:24336289"
FT   MUTAGEN         523
FT                   /note="D->Q: Increased permeability of dimethylamine and
FT                   trimethylamine and decreased permeability of magnesium."
FT                   /evidence="ECO:0000269|PubMed:23212381"
FT   MUTAGEN         525
FT                   /note="D->K: Increased permeability of dimethylamine and
FT                   trimethylamine and decreased permeability of magnesium."
FT                   /evidence="ECO:0000269|PubMed:23212381"
FT   MUTAGEN         530
FT                   /note="D->A: Does not affect ion channel activity."
FT   MUTAGEN         566..805
FT                   /note="Missing: Loss of channel activity. No effect on
FT                   expression at the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:25820328"
FT   MUTAGEN         568
FT                   /note="K->A,D,E: Loss of channel activity."
FT                   /evidence="ECO:0000269|PubMed:29425510"
FT   MUTAGEN         581..805
FT                   /note="Missing: Loss of channel activity. No effect on
FT                   expression at the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:25820328"
FT   MUTAGEN         594..599
FT                   /note="Missing: Loss of
FT                   phosphatidylinositol-4,5-bisphosphate binding."
FT                   /evidence="ECO:0000269|PubMed:29425510"
FT   MUTAGEN         594
FT                   /note="R->Q: Increased channel activity."
FT                   /evidence="ECO:0000269|PubMed:29425510"
FT   MUTAGEN         596
FT                   /note="R->Q: Increased channel activity."
FT                   /evidence="ECO:0000269|PubMed:29425510"
FT   MUTAGEN         598
FT                   /note="R->Q: Mildly increased channel activity."
FT                   /evidence="ECO:0000269|PubMed:29425510"
FT   MUTAGEN         599
FT                   /note="K->Q: Mildly increased channel activity."
FT                   /evidence="ECO:0000269|PubMed:29425510"
FT   MUTAGEN         622..805
FT                   /note="Missing: No effect on channel activity. No effect on
FT                   expression at the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:25820328"
FT   MUTAGEN         710
FT                   /note="L->A: Abolishes homooligomer formation; when
FT                   associated with A-714; A-717; A-728; A-731 and A-735."
FT                   /evidence="ECO:0000269|PubMed:22193359"
FT   MUTAGEN         714
FT                   /note="V->A: Abolishes homooligomer formation; when
FT                   associated with A-710; A-717; A-728; A-731 and A-735."
FT                   /evidence="ECO:0000269|PubMed:22193359"
FT   MUTAGEN         717
FT                   /note="L->A: Abolishes homooligomer formation; when
FT                   associated with A-710; A-714; A-728; A-731 and A-735."
FT                   /evidence="ECO:0000269|PubMed:22193359"
FT   MUTAGEN         728
FT                   /note="I->A: Abolishes homooligomer formation; when
FT                   associated with A-710; A-714; A-717; A-731 and A-735."
FT                   /evidence="ECO:0000269|PubMed:22193359"
FT   MUTAGEN         731
FT                   /note="V->A: Abolishes homooligomer formation; when
FT                   associated with A-710; A-714; A-717; A-728 and A-735."
FT                   /evidence="ECO:0000269|PubMed:22193359"
FT   MUTAGEN         735
FT                   /note="L->A: Abolishes homooligomer formation; when
FT                   associated with A-710; A-714; A-717; A-728 and A-731."
FT                   /evidence="ECO:0000269|PubMed:22193359"
FT   CONFLICT        13
FT                   /note="Q -> H (in Ref. 1; AAD41638)"
FT                   /evidence="ECO:0000305"
FT   TURN            102..104
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           105..118
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   TURN            119..121
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           127..137
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           148..150
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           157..160
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   TURN            164..169
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          183..185
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          188..194
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          202..205
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          207..210
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          229..232
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          238..240
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          243..246
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           250..253
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          261..264
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           278..290
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          298..309
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   TURN            310..313
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          314..323
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          333..339
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           356..375
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           385..419
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           429..451
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           452..454
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           482..498
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          499..502
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          504..506
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           511..521
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   TURN            526..532
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   STRAND          534..536
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           537..559
FT                   /evidence="ECO:0007829|PDB:6DU8"
FT   HELIX           704..731
FT                   /evidence="ECO:0007829|PDB:3TE3"
FT   HELIX           734..741
FT                   /evidence="ECO:0007829|PDB:4GIF"
SQ   SEQUENCE   805 AA;  91982 MW;  3714C07F4B71F9C6 CRC64;
     MNAVGSPEGQ ELQKLGSGAW DNPAYSGPPS PHGTLRVCTI SSTGPLQPQP KKPEDEPQET
     AYRTQVSSCC LHICQGIRGL WGTTLTENTA ENRELYIKTT LRELLVYIVF LVDICLLTYG
     MTSSSAYYYT KVMSELFLHT PSDTGVSFQA ISSMADFWDF AQGPLLDSLY WTKWYNNQSL
     GHGSHSFIYY ENMLLGVPRL RQLKVRNDSC VVHEDFREDI LSCYDVYSPD KEEQLPFGPF
     NGTAWTYHSQ DELGGFSHWG RLTSYSGGGY YLDLPGSRQG SAEALRALQE GLWLDRGTRV
     VFIDFSVYNA NINLFCVLRL VVEFPATGGA IPSWQIRTVK LIRYVSNWDF FIVGCEVIFC
     VFIFYYVVEE ILELHIHRLR YLSSIWNILD LVVILLSIVA VGFHIFRTLE VNRLMGKLLQ
     QPNTYADFEF LAFWQTQYNN MNAVNLFFAW IKIFKYISFN KTMTQLSSTL ARCAKDILGF
     AVMFFIVFFA YAQLGYLLFG TQVENFSTFI KCIFTQFRII LGDFDYNAID NANRILGPAY
     FVTYVFFVFF VLLNMFLAII NDTYSEVKEE LAGQKDELQL SDLLKQGYNK TLLRLRLRKE
     RVSDVQKVLQ GGEQEIQFED FTNTLRELGH AEHEITELTA TFTKFDRDGN RILDEKEQEK
     MRQDLEEERV ALNTEIEKLG RSIVSSPQGK SGPEAARAGG WVSGEEFYML TRRVLQLETV
     LEGVVSQIDA VGSKLKMLER KGWLAPSPGV KEQAIWKHPQ PAPAVTPDPW GVQGGQESEV
     PYKREEEALE ERRLSRGEIP TLQRS
//
